Literature DB >> 24728165

NR3C1 polymorphisms in Brazilians of Caucasian, African, and Asian ancestry: glucocorticoid sensitivity and genotype association.

Manoel Carlos L A Souza1, Clarissa S Martins1, Ivan M Silva-Junior1, Rosangela S Chriguer1, Ana C Bueno2, Sonir R Antonini2, Wilson Araújo Silva3, Marco A Zago1, Ayrton C Moreira1, Margaret de Castro1.   

Abstract

OBJECTIVE: The Brazilian population has heterogeneous ethnicity. No previous study evaluated NR3C1 polymorphisms in a Brazilian healthy population.
MATERIALS AND METHODS: We assessed NR3C1 polymorphisms in Brazilians of Caucasian, African and Asian ancestry (n = 380). In a subgroup (n = 40), we compared the genotypes to glucocorticoid (GC) sensitivity, which was previously evaluated by plasma (PF) and salivary (SF) cortisol after dexamethasone (DEX) suppression tests, GC receptor binding affinity (K d ), and DEX-50% inhibition (IC 50 ) of concanavalin-A-stimulated mononuclear cell proliferation. p.N363S (rs6195), p.ER22/23EK (rs6189-6190), and BclI (rs41423247) allelic discrimination was performed by Real-Time PCR (Polymerase Chain Reaction). Exons 3 to 9 and exon/intron boundaries were amplified by PCR and sequenced.
RESULTS: Genotypic frequencies (%) were: rs6195 (n = 380; AA:96.6/AG:3.14/GG:0.26), rs6189-6190 (n = 264; GG:99.6/GA:0.4), rs41423247 (n = 264; CC:57.9/CG:34.1/GG:8.0), rs6188 (n = 155; GG:69.6/GT:25.7/TT:4.7), rs258751 (n = 150; CC:88.0/CT:10.7/TT:1.3), rs6196 (n = 176; TT:77.2/TC:20.4/CC:2.4), rs67300719 (n = 137; CC:99.3/CT:0.7), and rs72542757 (n = 137; CC:99.3/CG:0.7). The rs67300719 and rs72542757 were found only in Asian descendants, in whom p.N363S and p.ER22/23EK were absent. The p.ER22/23EK was observed exclusively in Caucasian descendants. Hardy-Weinberg equilibrium was observed, except in the Asian for rs6188 and rs258751, and in the African for p.N363S. The K d , IC 50 , baseline and after DEX PF or SF did not differ between genotype groups. However, the mean DEX dose that suppressed PF or SF differed among the BclI genotypes (P = 0.03). DEX dose was higher in GG- (0.7 ± 0.2 mg) compared to GC- (0.47 ± 0.2 mg) and CC-carriers (0.47 ± 0.1 mg).
CONCLUSION: The genotypic frequencies of NR3C1 polymorphisms in Brazilians are similar to worldwide populations. Additionally, the BclI polymorphism was associated with altered pituitary-adrenal axis GC sensitivity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24728165     DOI: 10.1590/0004-2730000002868

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  5 in total

Review 1.  A biocultural approach to psychiatric illnesses.

Authors:  Eric C Shattuck
Journal:  Psychopharmacology (Berl)       Date:  2019-02-05       Impact factor: 4.530

2.  The interplay between genetic variation and gene expression of the glucocorticoid receptor gene NR3C1 and blood cortisol levels on verbal memory and hippocampal volumes.

Authors:  Sandra Van der Auwera; Johanna Klinger-König; Katharina Wittfeld; Jan Terock; Anke Hannemann; Robin Bülow; Matthias Nauck; Uwe Völker; Henry Völzke; Hans Jörgen Grabe
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-05-17       Impact factor: 5.270

3.  Association Between NR3C1 Gene Polymorphisms and Toxicity Induced by Glucocorticoids Therapy in Saudi Children with Acute Lymphoblastic Leukemia

Authors:  Refaat El-Fayoumi; Magda Hagras; Adel Abozenadaha; Waleed Bawazir; Thoraia Shinawi
Journal:  Asian Pac J Cancer Prev       Date:  2018-05-26

4.  Glucocorticoid receptor mutations and clinical sensitivity to glucocorticoid in Chinese multiple sclerosis patients.

Authors:  Tian Song; Haoxiao Chang; Li Du; Linlin Yin; Fudong Shi; Xinghu Zhang
Journal:  Neurol Sci       Date:  2020-04-10       Impact factor: 3.307

5.  Association between the Three Polymorphisms of the Glucocorticoid Receptor Gene and the Early Clinical Outcome in Kidney Transplantation Patients.

Authors:  Shaghayegh Mottaghi; Mohammad Mahdi Sagheb; Negar Azarpira; Faezeh Abdizadeh; Romina Faeghi; Iman Karimzadeh
Journal:  Iran J Med Sci       Date:  2021-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.